Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in severe COVID-19
IRCT20210408050899N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Mortality rate, Hospitalized in the intensive care unit and 2 more. Started Apr 2021; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210408050899N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210408050899N1.